Aminopeptidase N (AP-N) inhibitor is a reversible inhibitor of AP-N CD13 (IC50 = 25 μM). It is selective for AP-N CD13 over matrix metalloproteinase-9 (MMP-9), angiotensin converting enzyme (ACE), neutralendopeptidase (NEP), γ-glutamyl transpeptidase, and the serine proteases dipeptidyl peptidase 4 (DPP-4) and cathepsin G at a concentration of 1 mM. AP-N inhibitor is non-cytotoxic to U937 cells at a concentration of 100 μM.
SCH-42354 is a potent, orally active inhibitor of neutralendopeptidase (NEP), serving as the active form of the prodrug SCH-42495. By inhibiting NEP hydrolysis, SCH-42354 enhances the activity of atrial natriuretic peptide (ANP) and prevents the hydrolysis of leu-enkephalin and ANF with IC50 values of 8.3 nM and 10.0 nM, respectively. Furthermore, SCH-42354 exhibits antihypertensive activity [1] [2].
GLP-1(28-36)amide, a C-terminal nonapeptide derived from the cleavage of GLP-1 by neutralendopeptidase (NEP), is a significant product. It functions as an antioxidant and primarily targets the mitochondrion, where it effectively inhibits mitochondrial permeability transition (MPT). This compound exhibits anti-diabetic properties and demonstrates cardioprotection effects[1].